Changes of Serum Concentrations of Brain-Derived Neurotrophic Factor (BDNF) during Treatment with Venlafaxine and Mirtazapine: Role of Medication and Response to Treatment
In line with a recent meta-analysis [ 14 ] , an epidemiological study (n = 962) found serum BDNF to be low in currently depressed subjects and to be normalized in remission, while antidepressants were diff erentially related to serum BDNF (St. John's wort > SSRI > venlafaxine > TCA > mirtazapine) [ 15 ] . Thus, antidepressants may diff er in their ability to induce BDNF. A small case series showed sertraline having early, venlafaxine late and some antidepressants, like escitalopram, no eff ect on serum BDNF [ 16 ] . Negative fi ndings with regard to venlafaxine [ 17 ] emerged in other studies, while mirtazapine's eff ects on serum BDNF have never been studied. Most treatment studies did not specifi cally consider treatment response as a potential factor for BDNF regulation or studied only treatment responders [ 18 -21 ] , while others found increasing serum BDNF in female responders to antidepressant treatment only [ 22 ] or no association with treatment response at all [ 17 , 23 ] . Taken together, the eff ect of antidepressants on serum BDNF is undisputed, while it is unclear whether all classes of antidepressants aff ect Introduction ▼ Next to evidence demonstrating that stress decreases the expression of brain-derived neurotrophic factor (BDNF) leading to structural damage in limbic neurons, the BDNF-stimulating eff ect of antidepressants contributed to the formulation of the "neurotrophin hypothesis of depression" [ 1 , 2 ] . In rodents, chronic electroconvulsive treatment or antidepressant treatment enhanced the expression of hippocampal BDNF and prevented damaging eff ects of stress [ 3 , 4 ] . BDNF infusion in the hippocampus produced an antidepressant eff ect in various behavioral models of depression suggesting BDNF to be involved in the therapeutic action of antidepressants [ 5 ] . Most antidepressants, including venlafaxine [ 6 , 7 ] and mirtazapine [ 8 ] , may increase the hippocampal expression of BDNF, while others did not (fl uoxetine [ 9 , 10 ] ; tranylcypromine, fl uoxetine, desipramine [ 11 ] ; citalopram [ 12 ] ; escitalopram [ 13 ] ). BDNF equally and whether the eff ect is confi ned to treatment responders. Therefore, we intended (a) to compare serum BDNF between healthy controls and depressed subjects, (b) to study the eff ect of antidepressant treatment on serum BDNF, (c) to disentangle the eff ects of venlafaxine vs. mirtazapine and treatment response on serum BDNF and (d) to test whether serum BDNF is related to platelet numbers or volume.
Material and Methods

▼
Patients and healthy controls
We included adult inpatients with a major depressive episode diagnosed according DSM-IV and a score of at least 18 points on the Hamilton depression rating scale (HDRS, 21 items . Healthy controls were recruited by advertisement. Screening procedures included a psychiatric interview, physical examination, laboratory analyses and brain imaging (patients only). Exclusion criteria were a lifetime diagnosis of schizophrenia, schizoaff ective disorder or bipolar disorder, substance dependence and pre-treatment with venlafaxine, mirtazapine, fl uoxetine or long-acting antipsychotics during the current episode. Also, we excluded subjects with incomplete or haemolytic samples or baseline BDNF serum concentrations above mean plus 5 SDs (1 patient: male, 52 years). Semi-standardized diagnostic interviews revealed no current and lifetime axis I disorder, especially aff ective disorders, in healthy controls. All subjects provided written informed consent and the study was approved by the local ethics committee.
Study design
Patients were kept off psychiatric medication for a period of at least 6 days (week − 1), after which they received randomized (pre-defi ned allocation list), although open label treatment with either venlafaxine (fi nal dosage: 203 ± 47 mg) or mirtazapine (fi nal dosage: 46 ± 9 mg) in fl exible dosages for 4 weeks. With the exception of lorazepam (33/55 patients; mean total dosage 5.1 ± 8.7 mg) and zolpidem (11/55 patients; mean total dosage 44.4 ± 86.4 mg), no additional psychotropic medication was allowed throughout the study. Compliance during inpatient treatment was assured by ward staff . Psychopathology was assessed by the treating psychiatrist (MG, BS) once a week by means of the HDRS. Both clinicians were experienced and blind with regard to BDNF measures. However, there was no formal HDRS training. Patients with less than 18 points at the end of the drug-free run-in period or a drop of ≥ 10 points during that period (week − 1) were excluded from the study as responders during washout. Remission was defi ned as a fi nal HDRS score of ≤ 7 [ 24 ] .
Laboratory methods
On the mornings of day − 1 and day 28 blood was drawn, centrifuged (800 × g for 15 min) and serum samples stored at − 80 °C until BDNF concentrations were determined. BDNF serum concentrations were quantifi ed by a modifi ed ELISA (Promega Co., Madison, WI, USA) as described in detail previously [ 25 , 26 ] . Endogenous BDNF levels were measured in the rethawed serum samples using commercial ELISA kits according to the manufacturer's instructions (Promega Inc., USA) but adapted to a fl uorometric technique. Briefl y, microtiter plates (Thermoscientifi c; microfl uor2Black, 96-well, fl at-bottom) were coated with 100 μL/well of primary monoclonal anti-BDNF antibody diluted 1:1 000 in carbonate buff er (pH 9.6). After an overnight incubation at 4 °C the plates were washed once with washing buff er (Tris-buff ered saline with 0.05 % NP-40). As a blocking step, 200 μL of Block & Sample Buff er 1 × (Promega) were added into each well and incubated for 1 h in the dark at room temperature. After washing the plates 5 times with washing buff er, 100 μL of the samples (diluted 1:200 in Block & Sample Buff er 1 × ), recoveries [serum added with a known concentration of hBDNF (Alomone Labs)] and standards were added. The samples were measured in triplicate, the standards in duplicate and the recoveries in monoplicate. After an incubation step of 2 h in the dark at room temperature, the plates were washed 5 times with washing buff er. 100 μL of the secondary anti-BDNF polyclonal antibody (Promega) diluted 1:500 in Block & Sample Buff er 1 × were added into each well, followed by an incubation step of 2 h in the dark at room temperature. After washing 5 times with washing buff er again, 100 μL of anti-chicken IgY alkaline phosphatase conjugate (Abcam) diluted 1:2 000 in Block & Sample Buff er 1 × were added into each well and incubated for 1.5 h in the dark at room temperature. This incubation is followed by washing 5 times with washing buff er and 2 times with substrate buff er (0.1 M sodium phosphate at pH 8.7; 1 mM MgCl 2 ). Enzyme reaction was started by adding 50 μL AttoPhos Substrate Set (Roche Diagnostics GmbH) into each well, incubating over night in the dark in a moist chamber at room temperature. The reaction was stopped by adding 200 μL Stop Solution (0.15 M glycine; pH 10.5) into each well. The emission was measured with a fl uorescence photometer (excitation wavelength 485 nm, emission wavelength 538 nm). This assay has a detection limit of 0.7 pg/mL serum BDNF, the coeffi cients of inter-and intra-assay variation are 34.1 % and 6.7 %, respectively [ 23 ] . Since the intra-assay variation is much less than the inter-assay variation, the corresponding pre-and post-treatment samples of patients were always measured in the same BDNF assay.
Statistics
Univariate and analysis of variance with repeated measures (ANOVA-rm) using treatment (pre vs. post), medication (mirtazapine vs. venlafaxine) and outcome (remission vs. nonremission; relative change of HDRS score) as independent variables as well as Pearson's correlations were used as appropriate. Posthoc tests were performed with a 2-tailed signifi cance value set to 0.05. Data are reported as means ± standard deviations. . There was no diff erence in total usage of lorazepam between the group treated with mirtazapine (6.0 ± 9.1 mg) and the group treated with venlafaxine (5.3 ± 12.3 mg). ANOVA-rm revealed a signifi cant interaction eff ect of "treatment" × "medication" (Wilk's lambda = 0.910, F 1,51 = 5.04, p = 0.029) and a trend eff ect of borderline signifi cance for a "treatment" × "outcome" interaction (Wilk's lambda = 0.928, F 1,51 = 3.93, p = 0.053) on serum BDNF. There was no eff ect of "treatment" (repeated measures) and no signifi cant "treatment" × "outcome" × "medication" interaction. BDNF serum concentrations increased in patients remitting during treatment with mirtazapine (6.21 ± 4.22-8.50 ± 5.40 ng/mL, paired T = − 2.81, p = 0.017), but not venlafaxine (8.50 ± 3.91-8.61 ± 6.91 ng/mL, n.s.).
Results
▼
In non-remitting patients, there was no change of serum BDNF in mirtazapine-treated patients (7.20 ± 4.33-7.55 ± 4.05 ng/mL, n.s.), while BDNF serum concentrations signifi cantly declined in venlafaxine-treated patients (6.83 ± 3.42-5.11 ± 1.80 ng/mL, paired T = 2.439, p = 0.035) (see • ▶ Fig. 1 ). Controlling for age or sex did not change the fi ndings ( • ▶ Fig. 1 ). Accordingly, the relative change of serum BDNF (t 28 -t −1 /t −1 ) depended on "medication" (F 1,51 = 11.2, p < 0.001) and relative change of HDRS rating (F 1,51 = 4.4, p = 0.04). Platelet number at the time of sampling for BDNF (available in 37 patients) slightly increased over time (pre vs. post: 270.351 ± 84.280 vs. 284.838 ± 103.523 n/mL, Wilk's lambda = 0.880, F 1,31 = 4.51, p = 0.041), while ANOVA-rm did not reveal signifi cant eff ects of "treatment" × "medication" or "treatment" × "outcome" interactions (all F < 0.6, n.s.). Platelet volume (available in 37 patients) did not change during treatment (pre vs. post: 8.0 ± 0.86 vs. 8.1 ± 0.89 fl , n.s.) and there was no eff ect of "medication" or "outcome" (all F < 1.7, n.s.). Neither platelet number nor volume at baseline were related to BDNF serum concentrations (r = 0.195, r = 0.028; both n.s.).
Discussion
▼
In our study, serum BDNF did not diff er between depressed patients and healthy controls and, in contrast to earlier fi ndings [ 27 ] , within the group of patients serum BDNF was not related to severity of depression. Of course, we cannot exclude that this negative fi nding is due to the small healthy control sample size, the moderate severity of depression or carry-over eff ects of antidepressant pre-treatment. While the small sample size and uneven gender distribution may have not allowed us to adequately assess the eff ects of diagnosis and gender, the sample size was considered suffi cient to analyze treatment eff ects. During antidepressant treatment, the change of serum BDNF depended on medication (mirtazapine > venlafaxine) and clinical outcome (remission > non-remission). Antidepressants are thought to up-regulate the expression of cerebral BDNF and its receptor trkB [ 28 ] and to increase adult venlafaxine rem.
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pre-treatment post-treatment neurogenesis [ 29 , 30 ] which might be at the core of antidepressant activity. Recent studies in animal models of depression demonstrated that antidepressant classes diff er in their potential to induce hippocampal BDNF mRNA changes [ 9 -13 ] . While there is evidence that diff erent classes of antidepressants differentially infl uence hypothalamus-pituitary-adrenal (HPA) axis parameters in humans [ 31 , 32 ] , there is only limited information on changes in BDNF serum concentrations after administration of diff erent antidepressants. Both, cross-sectional epidemiological [ 15 ] as well as longitudinal studies support the hypothesis that antidepressants have heterogeneous eff ects on serum BDNF [ 16 , 17 , 23 ] . Only few studies considered response to treatment to play a role in antidepressants' eff ects on serum BDNF. Our data support the notion that both, choice of medication and, with borderline signifi cance, treatment response are relevant for the eff ects on serum BDNF. Interestingly, the eff ect of outcome diff ered between both drugs. We found increasing serum BDNF only in mirtazapine remitters, no change in mirtazapine nonremitters and venlafaxine remitters, but a decline of serum BDNF in venlafaxine non-remitters. To the best of our knowledge, this is the fi rst report of declining serum BDNF during antidepressant treatment with a specifi c drug. Of course, most of our patients were not drug-naïve. Thus, declining serum BDNF concentrations during unsuccessful treatment with venlafaxine may be due to a weaker eff ect of venlafaxine on serum BDNF when compared to pre-treatment. The source and signifi cance of serum BDNF is not fully understood. Serum BDNF may be independent from platelet reactivity [ 33 ] and there is evidence that cerebral and peripheral BDNF are related [ 4 , 34 ] . BDNF has been shown to cross the blood-brain barrier by a high-capacity, saturable transport system [ 35 , 36 ] . However, it remains unclear whether serum BDNF refl ects or contributes to brain BDNF. A mirtazapine-mediated increase of BDNF seems feasible as also animal studies suggest an increase of BDNF during chronic mirtazapine treatment, at least in the hippocampus and the prefrontal cortex of rats [ 8 , 36 ] . Diff erential eff ects of mirtazapine [ 37 ] , which decreases platelet activity and venlafaxine [ 38 ] , which increases platelet activity, might explain our current observation. In this context we might miss the BDNF redistribution between platelets and plasma, which has been described during SSRI treatment [ 39 ] as we only studied serum concentrations. In contrast to most recent studies, we did not fi nd depressed patients and males to have lower BDNF serum concentrations when compared to controls and females [ 40 ] , respectively. This might be due to small sample size and uneven gender distribution. Apart from the obvious limitation due to the small sample size, our results should be interpreted with caution in view of the short drug-free interval before the start of the study, short duration of the antidepressant trial, the small group of healthy controls as well as the unusually high rate of patients being in remission after inpatient antidepressant treatment. These limitations may limit generalizability of our fi ndings. However, this is the fi rst randomized study comparing the eff ects of 2 antidepressants on serum BDNF and considering the clinical course as a potential factor. In humans, a polymorphism in the BDNF gene has been associated with depression-related personality traits, i. e., neuroticism [ 41 ] . Regrettably, the BDNF genotype was not analyzed, but could have contributed to both the negative fi nding with regard to diagnosis as well as the treatment eff ects. A subgroup of patients, but not controls, were given lorazepam and zolpidem in low dosages. So far, it is assumed that benzodiazepines do not aff ect BDNF levels [ 42 ] , except in the case of withdrawal or catatonia. Taken together, our data give evidence to the assumption that antidepressants may have diff erent eff ects on serum BDNF. The clinical course should be considered in future studies.
